Overview
Immune Checkpoints
Study immune checkpoint receptor/ligand interactions, T cell exhaustion and immune checkpoint inhibitor mechanisms using CRISPR-engineered immune and tumor cell models.
What is Immune Checkpoints ?
Immune checkpoints are regulatory pathways that maintain self-tolerance and modulate the amplitude of immune responses. Tumors exploit checkpoints like PD-1/PD-L1 and CTLA-4 to evade immune attack. Immune checkpoint inhibitors have revolutionized cancer therapy, and CRISPR screens identify novel checkpoint molecules and resistance mechanisms.
Key Research Applications
PD-1/PD-L1 pathway component knockout
Checkpoint inhibitor resistance screening
T cell exhaustion reversal studies
Novel immune checkpoint discovery
B7/CD28 family receptor functional analysis
Products
Featured/Popular Targets
ALL
CD274
CTLA4
CD276
CD70
TNFRSF9
Product name Cat.No. Species Gene ID
CD274 Knockout HEK293 Cell Line EDC07777 Human 29126 Details Get a Quote
CD276 Knockout HEK293 Cell Line EDJ-KQ12832 Human 80381 Details Get a Quote
CTLA4 Knockout HEK293 Cell Line EDC07546 Human 1493 Details Get a Quote
CD70 Knockout HEK293 Cell Line EDC07537 Human 970 Details Get a Quote
TNFRSF9 Knockout HEK293 Cell Line EDC07594 Human 3604 Details Get a Quote
CD274 Knockout A-549 Cell Line EDJ-KQ41970 Human 29126 Details Get a Quote
CD274 Knockout HCT 116 Cell Line EDC07704 Human 29126 Details Get a Quote
CD276 Knockout A-549 Cell Line EDJ-KQ41972 Human 80381 Details Get a Quote
CD276 Knockout HCT 116 Cell Line EDJ-KQ41973 Human 80381 Details Get a Quote
CD276 Knockout HeLa Cell Line EDJ-KQ41974 Human 80381 Details Get a Quote
CD70 Knockout A-549 Cell Line EDJ-KQ18455 Human 970 Details Get a Quote
TNFRSF9 Knockout A-549 Cell Line EDJ-KQ18483 Human 3604 Details Get a Quote
CD70 Knockout HeLa Cell Line EDJ-KQ19790 Human 970 Details Get a Quote
CD274 Knockout HeLa Cell Line EDC08222 Human 29126 Details Get a Quote
CD276 Knockout MG-63 Cell Line EDJ-KZ14 Human 80381 Details Get a Quote
Displaying Records 1 To 15 Of 30 Records
Contact Us
*
*
*
*
How did you hear about us: